Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib with HAIC/TACE in Advanced HCC
NCT04479527Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Apr 2021
- Primary completion
- Aug 2023
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04479527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479527.